(Q35116864)

6 August 2017

1 reference

title

CD22 as a target of passive immunotherapy (English)

1 reference

6 August 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12720147

28 December 2023

CD antigens

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12720147

B-lymphocyte differentiation antigens

28 December 2023

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12720147

28 December 2023

passive immunization

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12720147

28 December 2023

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

28 December 2023

author name string

Alessandra Cesano

1

1 reference

6 August 2017

Urte Gayko

2

1 reference

6 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12720147

28 December 2023

publication date

1 April 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0093775403700888?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

https://api.elsevier.com/content/article/PII:S0093775403700888?httpAccept=text/plain

28 December 2023

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

28 December 2023

1 reference

6 August 2017

volume

30

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

253-257

1 reference

CD23 and B-cell activation

6 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

28 December 2023

The human IgE network

2

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Regulation of IgE synthesis. Lessons from the study of IgE transgenic and CD23-deficient mice

28 December 2023

3

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Molecular structure of the gene and the 5'-flanking region of the human lymphocyte immunoglobulin E receptor

28 December 2023

4

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

A major house dust mite allergen disrupts the immunoglobulin E network by selectively cleaving CD23: innate protection by antiproteases

28 December 2023

5

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand

28 December 2023

6

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Phosphotyrosine-dependent association between CD22 and protein tyrosine phosphatase 1C

28 December 2023

7

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP

28 December 2023

8

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes

28 December 2023

9

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions

28 December 2023

11

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma

28 December 2023

12

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Identification of CD22 ligands on bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B cells

28 December 2023

13

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

CD22 is a negative regulator of B-cell receptor signalling

28 December 2023

14

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Hyperresponsive B cells in CD22-deficient mice

28 December 2023

15

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor

28 December 2023

16

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound.

28 December 2023

17

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling

28 December 2023

18

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Constitutive endocytosis and degradation of CD22 by human B cells

28 December 2023

19

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

28 December 2023

20

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

28 December 2023

21

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

28 December 2023

23

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Tuning antigen receptor signaling by CD22: integrating cues from antigens and the microenvironment.

28 December 2023

25

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2

28 December 2023

31

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA.

28 December 2023

33

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Phase I immunotoxin trial in patients with B-cell lymphoma

28 December 2023

34

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

28 December 2023

37

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma

28 December 2023

38

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma

28 December 2023

39

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody

28 December 2023

40

1 reference

https://api.crossref.org/works/10.1053/SONC.2003.50057

28 December 2023

Identifiers

1 reference

release_yz56qzjzong65gnkgjfxoottye

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yz56qzjzong65gnkgjfxoottye

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference